Imagine if I told you that the choices we make every single day, what we eat, how we move, and how we take care of ourselves can influence something as profound as our blood health. Today I want to share with you the science behind leukemia and how understanding our bodies not only gives us the power to make informed decisions but also gives us the knowledge to perform personal agency every 3 minutes. Every 3 minutes somewhere in the world a child is diagnosed with leukemia.A that could be a classmate, a fr ...

Group 1 - Compass Therapeutics, Inc. announced a public offering of 33,290,000 shares of common stock priced at $3.00 per share, along with pre-funded warrants for 6,710,000 shares priced at $2.9999 each, expecting gross proceeds of approximately $120 million [1][2] - The offering is expected to close on or about August 14, 2025, subject to customary closing conditions, with underwriters granted a 30-day option to purchase an additional 6,000,000 shares [1][2] - The net proceeds will be used for commercial readiness preparations, funding research and clinical development of product candidates, and general corporate purposes [2] Group 2 - Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint active bookrunning managers for the offering, with additional firms serving as lead and co-managers [3] - A shelf registration statement for the securities was filed with the SEC on August 30, 2024, and declared effective on September 6, 2024, with a preliminary prospectus supplement already filed [4] Group 3 - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics targeting multiple diseases [6] - The company’s scientific focus includes the relationship between angiogenesis, the immune system, and tumor growth, with a robust pipeline of product candidates designed to target critical biological pathways for effective anti-tumor responses [6]

Gut Microbiota & Health - Each human hosts approximately 40 trillion bacteria and 380 trillion viruses, significantly outnumbering the global human population [1] - Gut microbiota, including bacteria, viruses, and fungi, plays a crucial role in human health, aiding digestion, supporting the immune system, and overall well-being [2][3] - Disruptions in gut microbiota have been linked to various diseases, influencing medical approaches to consider the gut-organ axis in diagnosis and treatment [4][5] - Hygiene hypothesis suggests that exposure to diverse microbes in natural environments can strengthen the immune system, potentially reducing the risk of conditions like asthma [9][10] - Microbial composition is unique to each individual and can be indicative of health status, similar to a "microbial face ID" [11][12] Personalized Nutrition & Probiotics - Personalized nutrition, tailoring dietary recommendations to individual biology, is gaining importance for optimizing gut health [15] - Probiotics can restore gut microbiota balance, as demonstrated by the case of an elderly patient recovering from severe diarrhea post-COVID-19 [16][17] - *Akkermansia*, a bacterium discovered in 2004, shows potential in improving metabolism, assisting weight loss, and easing symptoms of type 2 diabetes [19] Fecal Microbiota Transplantation (FMT) & Market - Fecal microbiota transplantation (FMT) is an effective treatment for *Clostridioides difficile* (C. diff) infection, with a success rate of approximately 95% [20][21] - The global market focused on the microbiota is valued at approximately $14 billion USD per year, with $1 billion USD in human health, $7 billion USD in agriculture, and $6 billion USD in animal health [24]